Rep. Maria Elvira Salazar Sells Off Shares of Moderna, Inc. (NASDAQ:MRNA)

by · The Cerbat Gem

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Moderna, Inc. (NASDAQ:MRNA). In a filing disclosed on September 09th, the Representative disclosed that they had sold between $1,001 and $15,000 in Moderna stock on August 19th. The trade occurred in the Representative’s “UBS BROKERAGE ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

  • Sold $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 8/24/2026.
  • Purchased $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 8/19/2026.
  • Sold $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 8/19/2026.
  • Purchased $15,001 – $50,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 8/19/2026.
  • Sold $15,001 – $50,000 in shares of Chubb (NYSE:CB) on 8/19/2026.
  • Sold $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 8/12/2026.
  • Purchased $1,001 – $15,000 in shares of SpaceX (NASDAQ:SPCX) on 8/12/2026.
  • Purchased $1,001 – $15,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 8/7/2026.
  • Purchased $1,001 – $15,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 7/28/2026.
  • Purchased $15,001 – $50,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 7/28/2026.

Moderna Stock Up 5.4%

Shares of Moderna stock traded up $7.35 on Friday, reaching $143.97. The company’s stock had a trading volume of 15,383,796 shares, compared to its average volume of 33,437,252. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $176.66. The firm’s fifty day simple moving average is $92.35 and its two-hundred day simple moving average is $66.74. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $57.48 billion, a price-to-earnings ratio of -18.02 and a beta of 1.10.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same period in the prior year, the company posted ($2.13) earnings per share. The company’s quarterly revenue was up 2.1% on a year-over-year basis. Equities analysts anticipate that Moderna, Inc. will post -6.09 earnings per share for the current year.

Institutional Investors Weigh In On Moderna

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in Moderna during the second quarter valued at approximately $2,142,877,000. California State Teachers Retirement System raised its position in Moderna by 6,698.1% in the second quarter. California State Teachers Retirement System now owns 27,681,318 shares of the company’s stock worth $1,938,523,000 after acquiring an additional 27,274,128 shares during the period. Capital World Investors bought a new position in Moderna in the fourth quarter worth approximately $378,299,000. Invesco Ltd. boosted its stake in shares of Moderna by 15.7% during the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock worth $212,223,000 after acquiring an additional 1,115,131 shares during the last quarter. Finally, Theleme Partners LLP purchased a new position in shares of Moderna during the 2nd quarter worth $564,272,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In related news, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the transaction, the president directly owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This represents a 4.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 10.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on MRNA. Argus raised Moderna from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a research report on Friday, August 28th. CLSA raised shares of Moderna to an “outperform” rating in a report on Friday, August 28th. Jefferies Financial Group reiterated a “hold” rating on shares of Moderna in a research note on Wednesday, August 19th. Bank of America raised shares of Moderna from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 19th. Finally, Citigroup increased their price objective on shares of Moderna from $41.00 to $60.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $76.72.

View Our Latest Research Report on MRNA

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

  • Positive Sentiment: Momentum and upcoming data readouts supported the stock. Moderna rallied in Friday morning trading despite limited movement among peers. UBS reportedly identified three near-term “INT” data readouts, potentially giving investors multiple upcoming catalysts to anticipate. However, the reports did not provide detailed results or confirm that any readout will be positive. Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat Moderna Set for 3 Near-Term INT Data Readouts, UBS Says
  • Neutral Sentiment: Congressional trading coverage offers no clear Moderna-specific catalyst. A report discussing recent stock transactions by members of Congress included Moderna-related investor-monitoring activity, but it did not identify a material change in the company’s outlook or operations. Congressional Stock Transactions
  • Neutral Sentiment: Short-interest data appears unreliable. The report listed both current and prior short interest at zero and calculated a zero-day short-interest ratio, with an invalid percentage change. Therefore, it provides little useful information about short-covering or bearish positioning in Moderna.
  • Negative Sentiment: Industry commercialization hurdles remain a risk. Manufacturing complexity and other barriers could slow the development and commercialization of personalized mRNA cancer vaccines, highlighting longer-term execution risks for Moderna and its peers. mRNA Cancer Vaccines’ Biggest Barriers to Market

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Moderna

(Get Free Report)

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.

Recommended Stories